Pharmacogenetic tools for malaria and TB in the Developing World

Personalized Medicine

Volumn 5, Issue 6, 2008, Pages 627-639

  Ferreira, Pedro Eduardo ^a,b   Cavaco, Isa ^a,b   Gill, José Pedro ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF ALGARVE   (Portugal)

Author keywords

Adverse events; CYP2C8; Developing World; Malaria; N acetyltransferase 2; NAT2; Pharmacogenetics; TB; Translational medicine

Indexed keywords

4 AMINOQUINOLINE; AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER; ARTESUNATE; ARYLAMINE ACETYLTRANSFERASE; BENFLUMETOL; COARSUCAM; CYTOCHROME P450 2C8; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; MEFLOQUINE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG; WINTHROP;

AREA UNDER THE CURVE; DETOXIFICATION; DNA POLYMORPHISM; DRUG ACETYLATION; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ETHNICITY; GENE CLUSTER; GENE STRUCTURE; GENETIC VARIABILITY; HUMAN; LIVER TOXICITY; LONGEVITY; MALARIA; MAXIMUM PLASMA CONCENTRATION; MOLECULAR DYNAMICS; NEURITIS; NEUTROPENIA; PHARMACOGENETICS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ANALYSIS; TUBERCULOSIS;

EID: 57749191007     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.5.6.627     Document Type: Review

References (79)

1. Nosten F, White NJ: Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg. 77(Suppl. 6), 181-192 (2007).
2. Cox HS, Morrow M, Deutschmann PW: Long term efficacy of DOTS regimens for tuberculosis: systematic review. Br. Med. J. 336(7642), 484-487 (2008).
3. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R: Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J. Gastroenterol. Hepatol. 23(2), 192-202 (2008).
4. Taylor WR, White NJ: Antimalarial drug toxicity: a review. Drug Saf. 27(1), 25-61 (2004).
5. White NJ: Cardiotoxicity of antimalarial drugs, Lancet Infect. Dis. (8), 549-558 (2007).
6. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC: Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282(7), 677-686 (1999).
7. White NJ: Antimalarial drug resistance. J. Clin. Invest. 113(8), 1084-1092 (2004).
8. Sachs JD, Hotez PJ: Fighting tropical diseases. Science 311(5767), 1521 (2006).
9. Wu AC, Fuhlbrigge AL: Economic evaluation of pharmacogenetic tests. Clin. Pharmacol. Ther. 84(2), 272-274 (2008).
10. Grossman I: Routine pharmacogenetic testing in clinical practice: dream or reality? Pharmacogenomics 8(10), 1449-1459 (2007). J
11. Harries AD, Dye C: Tuberculosis. Ann. Trop. Med. Parasitol. 100(5-6), 415-431 (2006).
12. Selikoff IJ, Robitzek EH, Ornstein GG: Treatment of pulmonary tuberculosis with hydrazide derivatives of isonicotinic acid, JAMA 150, 973-980 (1952).
13. Jindani A, Doré CJ, Mitchison DA: Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care Med. 167(10), 1348-1354 (2003).
14. Mitchison DA: Role of individual drugs in the chemotherapy of tuberculosis. Int. J. Tuberc. Lung Dis. 4(9), 796-806 (2000).
15. Mitchison DA: Basic mechanisms of chemotherapy. Chest 76(Suppl. 6), 771-781 (1979).
16. Donald PR, Sirgel FA, Botha FJ et al.: The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 156(3 Pt 1), 895-900 (1997).
17. Donald PR, Sirgel FA, Venter A et al.: The influence of human N acetyltransferase genotype on the early bactericidal activity of isoniazid. Clin. Infect. Dis. 39, 1425-1430 (2004).
18. Weber WW: The acetylation genes and drug response. Oxford University Press, NY, USA (1987).
19. Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW: Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob. Agents Chemother. 41(12), 2670-2679 (1997).
20. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A et al.: Should we use N acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob. Agents Chemother. 49(5), 1733-1738 (2005).
21. Parkin DP, Vandenplas S, Botha FJ et al.: Trimodality of isoniazid elimination, phenotype and genotype in patients with tuberculosis. Am. J. Respir. Crit. Care Med. 155, 1717-1722 (1997).
22. Weiner MW, Burman A, Vernon D et al.: Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am. J. Respir. Crit. Care Med. 167, 1341-1347 (2003).
23. Hughes HB: On the metabolic fate of isoniazid. J. Pharmacol. Exp. Therap. 109, 444-452 (1953).
24. Blum M, Grant DM, McBride W, Heim M, Meyer UA: Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol. 9(3), 193-203 (1990).
25. Zang Y, Doll MA, Zhao S, States JC, Hein DW: Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis 28(8), 1665-1671 (2007).
26. Leff MA, Fretland AJ, Doll MA, Hein DW: Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype. J. Biol. Chem. 274, 34519-34522 (1999).
27. Deguchi T, Mashimo M, Suzuki T: Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J. Biol. Chem. 265(22), 12757-12760 (1990).
28. Kita T, Tanigawara Y, Chikazawa S et al.: N-acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients. Biol. Pharm. Bull. 24(5), 544-549 (2001).
29. Chen B, Li JH, Xu YM, Wang J, Cao XM: The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetylisoniazid in Chinese pulmonary tuberculosis patients. Clin. Chim. Acta 365(1-2), 104-108 (2006).
30. Hiratsuka M, Kishikawa Y, Takekuma Y et al.: Genotyping of the N acetyltransferase 2 polymurphism in the prediction of adverse drug reactions to isoniazid in Japanese patients. Drug Metab. Pharmacokinet. 17(4), 357-362 (2002).
31. Weber WW, Hein DW: N-acetylation pharmacogenetics. Pharmacol. Rev. 37, 25-79 (1985).
32. Cho HJ, Koh WJ, Ryu YJ et al.: Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis 87(6), 551-556 (2007).
33. Huang YS, Chern HD, Su WJ et al.: Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35(4), 883-889 (2002).
34. Possuelo LG, Castelan JA, de Brito TC et al.: Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur. J. Clin. Pharmacol. 64(7), 673-681 (2008).
35. Ohno M, Yamaguchi I, Yamamoto I et al.: Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int. J. Tuberc. Lung Dis. 4(3), 256-261 (2000).
36. Huang YS, Chern HD, Su WJ et al.: Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37(4), 924-930 (2003).
37. Kubota R, Ohno M, Hasunuma T, Iijima H, Azuma J: Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2. Eur. J. Clin. Pharmacol. 63(10), 927-933 (2007).
38. Deen JL, von Seidlein L, Dondorp A: Therapy of uncomplicated malaria in children: a review of treatment principles, essential drugs and current recommendations. Trop. Med. Int. Health 13 (9), 1111-1130 (2008).
39. Hatton CS, Peto TE, Bunch C et al.: Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1(8478), 411-414 (1986).
40. Neftel KA, Woodtly W, Schmid M, Frick PG, Fehr J: Amodiaquine induced agranulocytosis and liver damage. Br. Med. J. 292 (6522), 721-723 (1986).
41. Larrey D, Castot A, Pëssayre D et al.: Amodiaquine-induced hepatitis. A report of seven cases. Ann. Intern. Med. 104(6), 801-803 (1986).
42. Jewell H, Maggs JL, Harrison AC, O'Neill PM, Ruscoe JE, Park BK: Role of hepatic metabolism in the bioactivation and detoxification of amodiaquine. Xenobiotica 25, 199-217 (1995).
43. Clarke JB, Maggs JL, Kitteringham NR, Park BK: Immunogenicity of amodiaquine in the rat. Int. Arch. Allergy Appl. Immunol. 91(4), 335-342 (1990).
44. Tingle MD, Jewell H, Maggs JL, O'Neill PM, Park BK: The bioactivation of amodiaquine by human polymorphonuclear leucocytes in vitro: chemical mechanisms and the effects of fluorine substitution. Biochem. Pharmacol. 50, 1113-1119 (1995).
45. Olliaro P, Nevill C, LeBras J et al.: Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 348(9036), 1196-1201 (1996).
46. Bloland PB, Ruebush TK: Amodiaquine. Lancet 348(9042), 1659-1660 (1996).
47. Olliaro P, Mussano P: Amodiaquine for treating malaria. Cochrane Database Syst. Rev. (2), CD000016 (2003).
48. Adjuik M, Agnamey P, Babiker A et al.: Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomized, multicentre trial. Lancet 359(9315), 1365-1372 (2002).
49. Orrell C, Taylor WR, Olliaro P: Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquiue and artesunate. Tram. R. Soc. Trop. Med. Hyg. 95(5), 517-518 (2001).
50. Orrell C, Little F, Smith P et al.: Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers. Eur. J. Clin. Pharmacol. 64(7), 683-690 (2008).
51. Enayetallah AE, French RA, Thibodeau MS, Grant DF: Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J. Histochem. Cytochem. 52(4), 447-454 (2004).
52. Klose TS, Blaisdell JA, Goldstein JA: Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J. Biochem. Mol. Toxicol. 13(6), 289-295 (1999).
53. Li XQ, Bjorkman A, Andersson TB, Ridderstrom M, Masimirembwa CM: Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J. Pharmacol. Exp. Ther. 300(2), 399-407 (2002).
54. Gil J, Gil Berglund E: CYP2C8 and antimalaria drug efficacy. Pharmacogenomics, 8(2), 187-198 (2007).
55. Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL: Amodiaquine metabolism is impaired by common polymorphisms in CYP2CS: implications for malaria treatment in Africa. Clin. Pharmacol. Ther. 82(2), 197-203 (2007).
56. Cavaco I, Strömherg-Nörklit J, Kaneko A et al.: CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur. J. Clin. Pharmacol. 61(1), 15-18 (2005).
57. Dai D, Zeldin DC, Blaisdell JA et al.: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11 (7), 597-607 (2001).
58. Walsky RL, Obach RS: Validated assays for human cytochrome P450 activities. Drug Metab. Dispos. 32(6), 647-660 (2004).
59. Hruska MW, Frye RF, Langaee TY: Pyrosequencing method for genotyping cytochrome P450 CYP2C8 and CYP2C9 enzymes. Clin. Chem. 50(12), 2392-2395 (2004).
60. Weise A, Grundler S, Zaumsegel D et al.: Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotyping. Clin. Lab. 50(3-4), 141-148 (2004).
61. Adjei GO, Kristensen K, Goka BQ et al.: Effect of concomitant artesunate administration and CYP2C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria. Antimicrob. Agents Chemother. PMID: 18779360 (2008).
62. Shillcutt S, Morel C, Goodman C et al.: Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy. Bull. World Health Organ. 86(2), 101-110 (2008).
63. Bhattarai A, Ali AS, Kachur SP et al.: Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med. 4(11), E309 (2007).
64. Cavaco I, Asimus S, Peyrard-Janvid M et al.: The Vietnamese Khin population harbours particular N acetyltransferase 2 allele frequencies. Clin. Chem. 53(11), 1977-1979 (2007).
65. Okello D, Floyd K, Adatu F, Odeke R, Gargioni G: Cost and cost-effectiveness of community-based care for tuberculosis patients in rural Uganda. Int. J. Tuberc. Lung Dis. 7(9 Suppl. 1), S72-S79 (2003).
66. Floyd K, Skeva J, Nyirenda T, Gausi F, Salaniponi F: Cost and cost-effectiveness of increased community and primary care facility involvement in tuberculosis care in Lilongwe District, Malawi. Int. J. Tuberc. Lung Dis. 7(9 Suppl. 1), S29-S37 (2003).
67. Roy PD, Majumder M, Roy B: Pharmacogenomics of anti-TB drugs-related hepatotoxicity. Pharmacogenomics 9(3), 311-321 (2008).
68. Patin E, Barreiro LB, Sabeti PC et al.: Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes. Am. J. Hum. Genet. 78(3), 423-436 (2006).
69. Cavaco I, Reis R, Gil JP, Ribeiro V: CYP3A4*1B and NAT2*14 alleles in a native African population. Clin. Chem. Lab. Med. 41(4), 606-609 (2003).
70. Patin E,Harmant C, Kidd KK et al.: Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene. Hum. Mutat. 27(7), 720 (2006).
71. Sabbagh A Langaney A, Darlu P, Gérard N, Krishnamoorthy R, Poloni ES: Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet. 9, 21 (2008).
72. German P, Greenhouse B, Coates C et al.: Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin. Infect. Dis. 44(6), 889-891 (2007).
73. Mallel S, Phillips E, Carosi G et al.: PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008).
74. Ingelman-Sundberg M: Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N. Engl. J. Med. 358(6), 637-639 (2008).
75. Cavaco I, Gil JP, Gil-Berglund E, Ribeiro V: CYP3A4 and MDR1 alleles in a Portuguese population. Clin. Chem. Lab. Med. 41(10), 1345-1350 (2003).
76. Sabbagh A, Langaney A, Darlu P, Gérard N, Krishnamoorthy R, Poloni ES: Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet. 9, 21 (2008).
77. Leff MA, Fretland AJ, Doll MA, Hein DW: Novel human N acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype. J. Biol. Chem. 274 (49), 34519-34522 (1999).
78. Mount DL, Patchen LC, Nguyen-Dinh P, Barber AM, Schwartz IK, Churchill FC: Sensitive analysis of blood for amodiaquine and three metabolites by high-performance liquid chromatography with electrochemical detection. J.Chromatogr. 383(2), 375-386
79. Harrison AC, Kitteringham NR, Clarke JB, Park BK: The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochem. Pharmacol. 43(7), 1421-1430 (1992).